Baricitinib is Used for treating severe alopecia areata, COVID-19 in hospitalized adults requiring supplemental oxygen, ventilation, or ECMO, and rheumatoid arthritis. It was first introduced by Eli Lilly And Co in its drug Olumiant on May 31, 2018. 2 different companies have introduced drugs containing Baricitinib.

Baricitinib Patents

Given below is the list of patents protecting Baricitinib, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Olumiant	US11045474	Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections	Nov 30, 2032	Eli Lilly And Co
Olumiant	US9089574	Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections	Nov 30, 2032	Eli Lilly And Co
Olumiant	US8158616	Azetidine and cyclobutane derivatives as JAK inhibitors	May 31, 2032	Eli Lilly And Co
Olumiant	US11806555	Methods for treating hair loss disorders	Nov 02, 2031	Eli Lilly And Co
Olumiant	US9737469	Methods for treating hair loss disorders	Nov 02, 2031	Eli Lilly And Co
Olumiant	US8420629	Azetidine and cyclobutane derivatives as JAK inhibitors	Mar 10, 2029	Eli Lilly And Co

Add above patents to watchlist

Baricitinib's Family Patents

Full family tree

Baricitinib Generic API Manufacturers

Several generic applications have been filed for Baricitinib.

Given below is the list of companies who have filed for Baricitinib generic, along with the locations of their manufacturing plants worldwide.